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Bone Regeneration for Murine Femur Fracture
by Gelatin Hydrogels Incorporating Basic Fibroblast
Growth Factor with Different Release Profiles
Hiroyuki Furuya, MD,1,2 Yasuhiko Tabata, PhD, DMedSci, DPharm,1 and Kazuo Kaneko, MD, PhD2
Biodegradable hydrogels with three different water contents were prepared through the glutaraldehyde cross-
linking of gelatin with an isoelectric point of 5.0 under varied reaction conditions. The objective of this study is
to investigate the effect of time period of basic fibroblast growth factor (bFGF) release that is modified by the
hydrogel water content, on the bone regeneration. A bone fracture was prepared at the femur bone of mice,
while gelatin hydrogels incorporating bFGF or bFGF solution was applied at the fracture site. The gelatin
hydrogels incorporating bFGF exhibited significantly stronger bone regeneration than the bFGF solution, al-
though the extent depended on the water content of hydrogels. Bone regeneration induced by gelatin hydrogels
incorporating bFGF increased with a decrease in their water content. Histological and biochemical examina-
tions indicated that the area of bone tissue newly formed and the level of osteogenic genes were enhanced for
the hydrogels incorporating bFGF of lower water content compared with those of higher one. It is possible that
the hydrogels that slowly degraded released bFGF for a longer time period, resulting in an enhanced bone
regeneration. It is concluded that the time profile of bFGF release is one of the factors contributing to the bFGF-
induced bone regeneration.
Introduction
In the situation when millions of fractures occur an-nually, the majority heal satisfactorily, but 5–10% lead to
delayed union or nonunion. The impaired fracture healing
results in pseudoarthrosis or skeletal deformity that may
cause functional disability. Not only for the treatment of
fracture healing but also for that of substantial bone loss in
osteoporosis patients, bioactive agents to stimulate bone
formation are quite important in the orthopedic field.1
Among the growth factors for tissue regeneration is basic
fibroblast growth factor (bFGF) that is a potent mitogen for
mesenchymal cells, while it induces neovascularization2,3
and osteogenesis4–14 or accelerates nerve regeneration.15–17
It has been reported that bFGF can stimulate bone forma-
tion.8–10 However, when used in the free form, bFGF does
not always exhibit in vivo biological activity expected be-
cause of its short half-life in vivo. As a practical method to
overcome this problem, some researches have been reported
on the controlled release of bFGF over an extended time
period by the use of different carriers.12–15,17–21 We have
explored a biodegradable hydrogel of acidic gelatin that
enables bFGF to achieve the controlled release at the site of
action,22 resulting in the enhancement of bFGF-induced
bone regeneration. In this release system, bFGF is im-
mobilized in the hydrogel matrix mainly through the ionic
interaction between bFGF and gelatin molecules. The bFGF
immobilized is released from the hydrogel matrix only when
the hydrogel is degraded to generate water-soluble gelatin
fragments. The time profile of bFGF release can be regu-
lated by changing that of hydrogel degradation. We have
demonstrated that the controlled release of bFGF from
gelatin hydrogel promotes the biological activity to induce
bone regeneration.13,14 The objective of this study is to in-
vestigate the effect of bFGF release profiles on the bone
regeneration in terms of microcomputed tomography (mCT),
histological, and genetic examinations.
Materials and Methods
Materials
A gelatin sample with an isoelectric point (IEP) of 5.0
(Mw= 99,000), prepared through an alkaline process of bo-
vine bone, was kindly supplied by Nitta Gelatin Co. An
aqueous solution of bFGF (Mw= 17,000, IEP= 9.6, 10mg/
mL) was kindly supplied by Kaken Pharmaceutical Co. Glu-
taraldehyde (GA), glycine, and other chemicals were obtained
from Wako Pure Chemical Industries, Ltd. Plank-Rychlo’s
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solution is aqueous solution of 0.3M aluminum chloride and
5wt% formic acid in HCl (3 vol%) for decalcification.23
Preparation of gelatin hydrogels
A gelatin derivative was prepared as described previ-
ously.22 Briefly, aqueous solution of 5 or 10wt% acid gel-
atin containing various concentrations of GA (Table 1) was
cast into a polytetrafluoroethylene mold. Crosslinking was
allowed to proceed for 12 h at 4C, and the resulting hy-
drogel sheets were immersed in 50mM glycine aqueous
solution at room temperature for 1 h to block the residual
aldehyde groups of GA. The hydrogels were rinsed three
times with double-distilled water (DDW) at room temper-
ature, followed by freeze-drying and sterilized with ethylene
oxide gas. The hydrogel weight was measured before and
after complete drying under a vacuum condition, and the
water content (the wt% of water in the wet hydrogel to the
wet hydrogel) was calculated from the two weights.
In vivo degradation test of gelatin hydrogels
To evaluate the in vivo degradation profile of gelatin hy-
drogels, the implantation of 125I-labeled hydrogels was per-
formed according to the method previously reported.24
Briefly, 20mL of [125I] Bolton–Hunter reagent solution in
benzene was completely evaporated at room temperature.
The resultant solid reagent was redissolved into 1mL of
phosphate-buffered solution (PBS, pH 7.5) and the resulting
solution (20mL) was dropped onto a freeze-dried gelatin
hydrogel, followed by leaving at 4C overnight to introduce
125I into the amino groups of gelatin. The radioiodinated
hydrogels were washed with DDW thoroughly to exclude the
uncoupled, free 125I molecules till to make the DDW radio-
activity to the background level. Following the implantation
into the back subcutis of mice, the hydrogels were taken out
at different time intervals to count the radioactivity remaining
by the gamma counter (Auto Well Gamma System ARC-380
CL; Aloka Co., Ltd.). Each experiment was independently
performed for three samples at each sampling time.
In vivo release test of bFGF from gelatin hydrogels
bFGF solution was radioiodinated according to the con-
ventional chloramine-T method as previously described.25
Briefly, 5mL of Na125 I was added into 200mL of bFGF
solution (150mg/mL) in 0.5M potassium PBS containing
0.5M NaCl. Then, 100mL of the same buffer containing
0.2mg/mL chloramine-T was added to the solution mixture.
After vortex mixing at room temperature for 2min, 100mL of
PBS containing 0.4mg sodium metabisulfite was added to the
reacting solution to stop the radioiodination. The solution
mixture was passed through a PD-10 desalting column (GE
Healthcare Life Sciences) to remove the uncoupled, free 125I
molecules from the 125I-labeled bFGF using PBS as an
eluting solution. The solution containing 100mg of bFGF
(20mL) was then dropped onto a freeze-dried gelatin hydro-
gel, followed by leaving at 4C overnight to obtain hydrogels
incorporating 125I-labeled bFGF. Following the implantation
into the back subcutis of mice, the hydrogels were taken out
at different time intervals to measure the radioactivity re-
maining by the gamma counter. Each experiment was inde-
pendently performed for three samples at each sampling time.
Animal experiments
C57BL/6 mice (6-week-old, male) were purchased from
Shimizu Laboratory Supply. During the experiment, all
animals were maintained in cages with free access to food
and water and 12 h lighting. All the animal experiments
were performed according to the Institutional Guidance of
Kyoto University on Animal Experimentation and under
permission by animal experiment committee of Institute for
frontier Medical Science, Kyoto University.
The experimental bone fracture was performed according
to the procedure with a locking needle described previous-
ly.26 The mice were anesthetized by the intraperitoneal in-
jection of pentobarbital sodium solution (35–40mg/kg body
weight). The operative site either on the left or right leg was
shaved, and the lateral parapatellar incision was performed to
mobilize the patellar tendon and to dislocate the patella me-
dially. At the intercondylar notch, an intramedullary canal
was opened by the injection needle of 24 gauge. Additionally,
the greater trochanter was drilled retrogradely over the in-
tramedullary cavity by using the same injection needle. After
removal of the needle, the femur was fractured using a side-
cutting diamond disk and a high-speed micromotor under an
abundant irrigation with sterile saline solution. A 24-gauge
injection needle was used for the locking of bone fracture.
The rotation stability of bone was achieved by flattening the
tip and the distal end. The locking needle was 0.55mm in
diameter and 15mm in length, whereas the spearhead and the
distal flattening were about 1.0-mm wide and 0.1–0.2-mm
flat. The bone fracture was fixed by locking needle inserted
intramedullary. Gelatin hydrogels with different water con-
tents incorporating 100mg of bFGF or 100mg bFGF solution
were applied around the bone fracture while the overlying
muscles were repositioned with an absorbable suture
(monodiox 6-0; Alfresa Pharma Co., Ltd). Then, the skin was
closed with a nonabsorbable suture (nylon 4-0; Bear Medical
Systems, Inc.). Each experimental group was composed of
three mice. The animals were sacrificed by the intravenous
administration of sodium pentobarbital at an overdose 2 and 4
weeks after application. The femur bone was retrieved and
fixed in 4wt% paraformaldehyde solution in PBS to assess
the bone regeneration by mCT and histological examination.
Histological examinations of bone tissues regenerated
The samples were fixed with 4wt% paraformaldehyde in
PBS at 4C for overnight 2 and 4 weeks after application.
For the histological examination, the samples were dec-
alcified with the Plank–Rychlo’s solution for 2 days, em-
bedded in paraffin, and sectioned at 4-mm thick at the defect
site, followed by staining with hematoxylin and eosin and











Gel 1 5 0.025 96.9– 0.004
Gel 2 5 0.05 93.3– 0.005
Gel 3 10 0.25 85.1– 0.003
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Masson’s trichrome. The images were taken under a mi-
croscope (AX80 Provis; Olympus Ltd.).
lCT of bone regenerated
The bone mineral density (BMD) was measured and
three-dimensional (3D) images of bone regenerated in the
femur bone were visualized by the CT scans (X-RAY CT
System, Latheta LCT200; Hitachi Aloka Medical, Ltd.).
Samples were scanned continuously with increments of 48-
mm thickness for slices and the voxel size was 24· 24 mm2.
The two-dimensional (2D) images were reconstructed and
submitted to the VG Studio MAX 2.0 software (Volume
Graphics GmbH) for processing to produce the 3D images
of bone regenerated. The BMD of each bone fracture was
measured at the 24· 24· 6000 mm3 region of interest. This
instrument was calibrated automatically.
Quantitative real-time polymerase chain reaction
Total RNA was purified from the femur bone using an
RNeasy Plus Mini Kit (Qiagen) according to the manufac-
turer’s protocol. cDNA was generated from 1 ng of whole
RNA using a SuperScript VILO cDNA Synthesis Kit (In-
vitrogen). cDNA was analyzed for content using an SYBR
Green-based, quantitative fluorescent PCR method (Applied
Biosystems). Fluorescence was detected with an Applied
Biosystems 7500 Real-Time PCR System (Applied Bio-
systems). The primers summarized in Table 2 were used.
The following polymerase chain reaction (PCR) conditions
were used: 95C for 15min followed by 40 cycles of 95C
for 15 s, 60C for 30 s, 72C for 30 s, followed by 72C for
10min. 18s was used as a housekeeping gene. Relative
quantification of genes involved with osteogenesis by using
the (ddCt) comparative threshold cycle method. The data for
the treatment groups are expressed as fold change relative to
the group of bFGF-free solution.
Statistical analysis
All the data were analyzed by Student’s t-test to assess
statistical significance between experimental groups and
p< 0.05 was accepted as significant. Experimental results
were expressed as the mean– standard deviation of the mean.
Results
Controlled release of bFGF from gelatin hydrogels
and hydrogel degradation
Figure 1A shows the time profiles of bFGF released from
gelatin hydrogels. An initial burst in bFGF release was seen
for the first day, but thereafter 65–75% of radioactivity was
released out from the hydrogels. The time period of bFGF
released prolonged with a decrease in the water content of
hydrogels.
Figure 1B shows the relationship of radioactivity re-
maining between bFGF incorporated in gelatin hydrogels
and the hydrogels of release carrier. Irrespective of the type
of gelatin hydrogels, a linear relationship of the radioactivity
remaining was observed. The time profiles of bFGF release
were well correlated with that of hydrogel degradation.
Bone regeneration at the femur fracture
Figure 2 shows the 3D images of bone tissue regenerated
in the femur fracture 2 and 4 weeks after application. At 2
weeks, cartilage tissues were regenerated, but little bone
tissue was observed around the fracture. At 4 weeks, new
bone tissues were regenerated for all the groups, although
the extent of gel 3 group was greater than that of other
groups. In relation to the union rate, at 2 weeks after ap-
plication, the period of the bone regeneration is in the re-
parative phase. It was difficult to recognize the bone
regeneration by mCT. At 4 weeks of application, for all
groups, the union of fracture site could be recognized by
mCT. Based on this, the union rate was 0% after 2 weeks of
application and 100% after 4 weeks of application in all
groups.
Figure 3 shows the BMD values of femur fracture after
treatment. Higher BMD was seen at the bone tissue re-
generated in the group of gel 1, 2, and 3 than the group of
bFGF-free and bFGF solution 2 weeks later. At 4 weeks,
significantly enhanced BMD was found for the group of gel
3 compared with other groups.
Figure 4 shows the histological section of femur fracture
2 and 4 weeks after application. At 2 weeks, cartilage tissues
were observed around the fracture site, especially for the
groups of gel 2 and gel 3. At 4 weeks, new bone tissues were
regenerated around the fracture site for all the groups. The
group of gel 3 exhibited significantly strong bone formation
compared with other groups.
Expression of osteocalcin and Runx2 mRNA in the
femur bone fracture
To investigate whether bFGF locally applied could affect
mineralization, the mRNA expression levels of osteocalcin
and Runx2 were estimated 1, 2, and 4 weeks after applica-
tion. Both of expression levels for the groups of gel 1, gel 2,
and gel 3 were significantly higher than those of bFGF-free
or bFGF solution 2 weeks after application. The levels for
gel 2 and 3 groups were significantly higher than those of
bFGF-free, bFGF solution, and gel 1 groups 2 weeks after
application. However, 1 week after application, there was no
significant difference in the mRNA expression levels of
osteocalcin and Runx2 for all groups.
Discussion
The present study investigates whether or not the time
period of bFGF released from gelatin hydrogels affects the
healing of a femur fracture bone, in particular on en-
dochrondral ossification. The results demonstrate that the
controlled release of bFGF for a longer time period
Table 2. Primers Used in Quantitative Real-Time
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significantly increased the area of bone tissue newly formed,
the BMD at the bone fracture, and the mRNA expression of
osteoblast-related osteocalcin and Runx2.
bFGF is a growth factor to trigger the proliferation of
capillary endothelial cells in addition to osteoblasts.27 Weiss
et al. reported that bFGF stimulated cells involved in os-
teogenesis and angiogenesis in a vascularized bone graft.28
Indeed, angiogenesis was observed around the skull defect
of bFGF-treated rabbits during the initial period. It is re-
ported that bFGF may be proliferative both for pre-
osteoblasts29 and marrow cells.30,31 A positive effect of
bFGF on the osteogenesis in the bone marrow has also been
found in vivo.32 The higher number of osteocytes incor-
porated into the bone site newly formed by bFGF may be
one reason to explain the phenomenon. It has been sug-
gested that bFGF, in fact, acts mainly on endosteal cells,
because the increased activity was observed in the endos-
teum, but not in the periosteum after the intravenous ad-
ministration of bFGF to rats.10,33 In conclusion, bFGF is
able to promote orthopic osteogenesis in the mice fracture
model, although to a limited degree. This is because bFGF
itself has a proliferative effect on cells committed to the
osteogenic lineage.
Our previous researches have demonstrated that the hy-
drogels prepared from gelatin with an IEP of 5.0 could re-
lease bFGF in a controlled fashion.14,22 The gelatin
hydrogels release bFGF either in the diffusion or hydrogel
degradation manner. bFGF without interacting with gelatin
molecules of hydrogel would be initially burst-released from
the hydrogels by the simple diffusion mechanism. The re-
maining bFGF is released as a result of gelatin hydrogel
degradation. The water content of hydrogels that affects
their degradability could be easily changed only by altering
the concentration of gelatin and GA used for the cross-
linking reaction (Table 1).
In addition to the time profile of bFGF release, that of
hydrogel degradation should be considered. The hydrogel
remaining in the bone defect will impair physically the
process of bone regeneration induced in the defects. It
is demonstrated that bone tissue formation is also influ-
enced by the degradation profile of carrier itself.34 To
break through the issue, in this study, the hydrogels were
not applied into the bone defect, but the site around the
defect.
Locally administered bFGF in solution is rapidly elimi-
nated from the applied site either passively by simple dif-
fusion, or actively by proteolysis or antibody neutralization
in the tissue.9,35–37 It is well recognized that endogenous
FGF is stored in the extracellular matrix (ECM) in vivo, and
released in the tissue to exert its biological activity fol-
lowing the ECM degradation by proteases.38 Previous
studies have revealed that osteogenic differentiation is
sensitive to the dose and duration of FGF exposure.39,40 It
would be ideal to supply the growth factor for the time
period long enough to promote the proliferation and dif-
ferentiation of osteogenic cells. The in vivo release tests
show that bFGF was retained at the site of hydrogels ap-
plied for a prolonged time period. Animal experiments
with 125I-labeled bFGF or gelatin demonstrated that the
retention period of bFGF in the body was in good accor-
dance with that of gelatin hydrogels. This indicates that
bFGF was released as a result of in vivo degradation of
the hydrogel matrix.36 The hydrogel of release carrier
with an optimal degradation profile will contribute to an
optimal release profile of bFGF incorporated to achieve
bFGF-induced bone regeneration. The merits to use the
FIG. 1. (A) In vivo release
profiles of basic fibroblast
growth factor (bFGF) from
gelatin hydrogels incorporat-
ing 125I-labeled bFGF after
implantation into the back
subcutis of mice: (6) gel 1,




rated in gelatin hydrogels and
125I-labeled hydrogels of re-
lease carrier.
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controlled release of osteogenic growth factors are not only
the efficient induction of bone regeneration, but also the
decrease in the dose.
Many research groups have used the same femur fracture
model to evaluate bone regeneration. The researches have
demonstrated the high reproducibility and reliability of the
fracture model.41–43
The present study clearly demonstrates that combination
with a good carrier enables bFGF to enhance the osteogenic
functions, leading to an enhanced healing of femur bone
FIG. 2. Three-dimensional
images of femur fracture of
mice 2 and 4 weeks after
application of bFGF-free so-
lution (A), 100mg of bFGF
solution (B), gel 1 incorpo-
rating 100mg of bFGF (C),
gel 2 incorporating 100mg
of bFGF (D), and gel 3 in-
corporating 100 mg of bFGF
(E). Color images available
online at www.liebertpub
.com/tea
FIG. 3. The bone mineral density of bone regenerated of the femur fracture of mice 2 and 4 weeks after application of bFGF-
free solution, 100mg of bFGF solution, gel 1 incorporating 100mg of bFGF, gel 2 incorporating 100mg of bFGF, and gel 3
incorporating 100mg of bFGF. *p< 0.05, significantly against the value of bFGF-free solution; {p< 0.05, significantly against the
value of bFGF solution; **p< 0.05, significantly against the value of gel 1 incorporating 100mg of bFGF; and {p< 0.05,
significantly against the value of gel 2 incorporating 100mg of bFGF.
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fracture. It is likely that the controlled release of bFGF from
the gelatin hydrogel takes place in the tissue around the
bone fracture site. We can say with certainty that the bFGF
released induced the bone regeneration at the femur fracture.
The bFGF-incorporated gelatin hydrogels with lower water
content showed higher BMD than those of higher one (Fig.
3). The prolonged acting of bFGF must be necessary to
allow osteogenic cells to proliferate and activate for bone
regeneration.
To evaluate the effect of bFGF on the osteogenic differ-
entiation of cells, the mRNA expression of osteocalcin and
Runx2 was examined. The bFGF released enhanced the
mRNA levels although they were higher for the hydrogels
for longer time periods of bFGF release. Osteocalcin of a
non-collagenous matrix protein is synthesized by mature
osteoblasts.44–47 Runx2 is known to be the critical tran-
scription factor for the development and differentiation of
osteoblasts.48–51 Runx2 upregulates bone sialoprotein and
osteocalcin, two major components of bone ECM synthe-
sized exclusively by osteoblastic cells.52 Previous re-
searches indicated that the Runx2 expression and
phosphorylation are activated by the FGF signaling via the
mitogen activated protein kinase pathway or the protein
kinase C pathway.53,54 Formation of a Runx2-smad osteo-
genic complex and subnuclear targeting are structurally and
functionally inseparable for the execution and completion of
BMP2 signaling for osteoblastogenesis.55 The osteogenic
differentiation would be promoted by the bFGF release,
resulting in an enhanced bone regeneration.
As FGF signaling exerts a direct effect on Runx2 acti-
vation, these functional relationships may enable researchers
to unravel the overall differentiation control mechanism by
which a single FGF2/FGFR signaling event can reciprocally
induce promotion and inhibition of osteoblast differentiation
in a stage-dependent manner. Canalis et al. demonstrated
that the stimulatory effect of bFGF on the osteoblastic
collagen synthesis was indirect and secondary to the mito-
genic effect. In addition, bFGF caused a direct inhibitory
effect on the osteoblastic function manifested by a decrease
in type I collagen synthesis, when calvariae were continu-
ously treated with bFGF. This inhibitory effect of bFGF was
selective for bone collagen synthesis, indicating that it was not
due to a generalized toxic effect.8 Although in vitro experi-
ment, Debiais et al. reported that bFGF induced opposite ef-
fects on osteocalcin synthesis and matrix mineralization in
early and late cultures. bFGF inhibited osteoblast differentia-
tion markers in less-mature cells and increased late-osteoblast
markers, such as osteocalcin, and matrix mineralization in
more mature cells indicates that the response of cells to bFGF
varies with the stage of cell maturation.56
It is apparent from Figure 5 that the time period of bFGF
release may be essential to promote bone induction activity.
FIG. 4. Histological sec-
tions of the femur fracture of
mice 2 (A, B) and 4 (C–E)
weeks after application of
bFGF-free solution (a),
100 mg of bFGF solution (b),
gel 1 incorporating 100 mg of
bFGF (c), gel 2 incorporating
100 mg of bFGF (d), and gel
3 incorporating 100 mg of
bFGF (e). Squares mean the
fracture site. The sections
were stained by hematoxylin
and eosin (A, C) and Mas-
son’s trichrome (B–E). (E)
High magnification of (D) at
bone fracture site. Color
images available online at
www.liebertpub.com/tea
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The bone regeneration at the fracture for the group of bFGF
solution was similar to that of bFGF-free solution (Fig. 5).
The ability of gelatin hydrogels incorporating bFGF to in-
duce bone regeneration greatly depended on their water
content (Figs. 3, 4C, 4D, and 5). It is likely that the fast-
degraded hydrogel could neither prolong the in vivo reten-
tion of bFGF nor protect the fracture from the ingrowth of
fibrous tissue. When the rate of hydrogel degradation is too
slow compared with that of bone regeneration at the femur
fracture, it is likely that the hydrogel remaining at the
fracture physically impairs bone regeneration, even though
bFGF is released over the long time period. Our previous
studies experimentally confirmed that gelatin hydrogels with
a low degradability physically impaired bone regeneration
induced by gelatin hydrogels incorporating osteogenic
growth factor both at the ulna and skull defects of rab-
bits.57,58 The osteoinduction activity of hydrogels with a
water content of 85.1wt% was significantly higher than that
FIG. 4. (Continued).
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of hydrogels with lower water content. The threshold period
of hydrogel degradation to start interfering bone regenera-
tion is unclear at present and optimal time periods that en-
hance bone formation in vivo should be investigated.
In this study, we successfully examined the time profile of
the degradation of gelatin hydrogel using the radioactivity
agents in vivo. Considering the release mechanism, it is
likely that bFGF molecules are released out being associated
with water-soluble gelatin fragment. The bFGF is released
as the result of hydrogel degradation. We previously ex-
amined the profile of the degradation of gelatin hydrogel and
of the release of bFGF using the radioactivity in vivo.22,25
We demonstrated that vascularization was remarkable
around the implantation site of gelatin hydrogels incorpo-
rating bFGF by histological examination. The amount of
tissue hemoglobin, which is a measure of bFGF-induced
neovascularization, notably increased within 1 day of im-
plantation of gelatin hydrogels incorporating bFGF.59
We also demonstrated that a rabbit model of a skull bone
defect was employed to evaluate the in vivo efficacy of
gelatin hydrogels incorporating bFGF in bone formation.
When implanted into a skull defect, the gelatin hydrogel
incorporating bFGF accelerated bone regeneration at the
skull defect and almost closed the defect after 12 weeks of
implantation and enhanced the BMD of the skull defect.13
Moreover, we previously demonstrated that gelatin hy-
drogel incorporating bFGF enhanced tissue survival of fin-
gertip amputations and restoration of blood flow of
Buerger’s disease in clinical study.60,61
Although in vitro studies and clinical trials provide ade-
quate techniques and instruments to improve our knowledge
on bone repair, animal studies still represent an essential tool
to analyze the biology of fracture healing.62 Accordingly,
numerous mammalian species, ranging from the mouse to the
sheep, have been introduced as models to study fracture
healing.63–65
Because of a more primitive bone structure without a
haversian system, small rodents, like mice and rats, are
thought to be less appropriate for bone healing studies
compared with larger animals. In contrast to larger rodents
and other mammalians, small rodents use resorption cavities
for bone remodeling during fracture healing, and this pro-
cess of remodeling has been shown similar to the haversian
remodeling in larger animals.
The small size of mice is challenging for the development
of a fracture model. Therefore, particularly large long bones,
such as the femur and the tibia, are thought to be the most
appropriate for studies on fracture healing.65,66
In contrast to the tibia, the mouse femur is a tubular bone
with a relatively consistent inner and outer diameters. Ac-
cordingly, different fracture sites within the diaphyseal part
of the bone show comparable callus responses. Because of
the straight longitudinal axis, standardized fracture stabili-
zation is easier in the femur. It is commonly argued that
FIG. 5. mRNA expression of osteocalcin (A–C) and Runx2 (D–F) was measured at 1 (A, D), 2 (B, E), and 4 weeks (C, F)
after application by quantitative reverse-transcription–polymerase chain reaction analysis. 18s mRNA from each sample
was used as an internal standard to normalize levels of total mRNA. * p < 0.05, significantly against the value of bFGF-free
solution; {p < 0.05, significantly against the value of bFGF solution; **p < 0.05, significantly against the value of gel 1
incorporating 100mg of bFGF.
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murine fracture models do not require biomechanical stan-
dardization because the predominance of research using
mouse models has focused on the molecular aspects of
fracture healing.
Nevertheless, the most established imaging techniques to
study murine fracture healing are high-resolution radiogra-
phy and 2D and 3D mCT. Using conventional X-ray tech-
niques, the size and radiologic density of the fracture callus
can be analyzed in living animals and resected bones.67–69
Common parameters to be evaluated by the mCT are the
tissue mineral density, total callus volume, and bone volume
fraction of the callus.70,71 In addition, the assessment of in
situ messenger RNA expression can be additionally sup-
ported by semiquantitative techniques, such as Northern blot
analysis and reverse-transcription PCR.72,73
In our study, the controlled release system for bFGF is
achieved to enhance in vivo bone regeneration with mice
femur fracture model. Moreover, the quantification mea-
surement of BMD demonstrated a significant increase in the
bone regeneration for mice femur fracture. Taken together,
these findings indicate that the gelatin hydrogel incorpo-
rating bFGF provides a benefit that will enable to achieve
bone regeneration for mice femur fracture.
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